Kedrion Biopharma plans to build a plant for production of the drug used in the treatment of patients with hemophilia

Tashkent, Uzbekistan (UzDaily.uz) -- Kedrion Biopharma Company plans to build a production line for the production of Coagulation Factor VIII.

Representatives of the company and the khokimiyat of the city of Tashkent discussed the prospects for building a production line of a unique medical drug used in the treatment of patients with hemophilia.

The estimated production cost is US$25 million. The project will create production facilities and laboratory facilities.

Following the visit, the guests scheduled to inspect several suitable sites for the construction and signing of a memorandum of cooperation.